Aandelen in “Farmaceutische Producten: Generisch”

Aandeel Datum Koers Evolutie
vlag Helix Biopharma Corp. 11/06 1,580 CAD
+3,95% 		+3,95%
vlag Hikma Pharmaceuticals 11/06 1.482,000 GBX
+1,30% 		+1,30%

Nieuws over “Farmaceutische Producten: Generisch”

10/06 · Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy  · Persbericht

10/06 · Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy  · Persbericht

8/06 · Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care · Persbericht

6/06 · INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Zoetis Inc. (ZTS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit · Persbericht

5/06 · Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea · Persbericht

4/06 · Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma · Persbericht

4/06 · Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea® · Persbericht

3/06 · ZTS DEADLINE: Levi & Korsinsky Reminds Zoetis Inc. Investors of Upcoming Securities Class Action Deadline · Persbericht

1/06 · Teva to Present at the Goldman Sachs Global Healthcare Conference · Persbericht

27/05 · Zoetis (ZTS) Securities Fraud Investigation - Levi & Korsinsky · Persbericht

21/05 · The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults · Persbericht

18/05 · Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution · Persbericht

18/05 · Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact · Persbericht

13/05 · Zoetis (ZTS) Securities Fraud Investigation - Levi & Korsinsky · Persbericht

4/05 · Teva to Present at the BofA Securities Health Care Conference · Persbericht

30/04 · Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets · Persbericht

29/04 · Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution · Persbericht

29/04 · Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy · Persbericht

15/04 · Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners · Persbericht

14/04 · Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics · Persbericht

30/03 · Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab) · Persbericht

Mijn selecties